Please login to the form below

trial data

This page shows the latest trial data news and features for those working in and with pharma, biotech and healthcare.

Boehringer bags FDA OK for Ofev in rare lung disease ILD

the trial data. ... The FDA approval comes on the back of the 576-patient SENSCIS trial reported earlier this year, which found that Ofev – a triple angiokinase inhibitor that simultaneously inhibits VEGF, PDGF and

Latest news

Can AZ’s Imfinzi challenge Tecentriq in small cell lung cancer?

New data shows improvement in overall survival. AstraZeneca has put the flesh on the bones of its CASPIAN trial of immuno-oncology drug Imfinzi in advanced small cell lung cancer (SCLC), ... The drugmaker first reported the top-line data from the phase 3
Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate

effectiveness watchdog has pledged to work with the company to resolve shortfalls in its data. ... One such expanded use would be Tuberous Sclerosis Complex, for which the company recently presented promising phase 3 trial data, which it expects to
BeiGene gets speedy US review for lymphoma drug zanubrutinib

The MCL filing is based on data from a phase 1/2 trial of BeiGene’s BTK inhibitor in patients with B-cell lymphomas, as well as an aggregate of 123 ... patients from a phase 2 trial of the drug in patients with relapsed or refractory MCL in China.
AZ’s Imfinzi combo bombs again in non-small cell lung cancer

from this trial to gain further insights to improve immuno-oncology approaches for patients with metastatic non-small cell lung cancer.”. ... Meanwhile, the PEARL trial is pitting Imfinzi against chemotherapy in first-line NSCLC.
Regeneron scores positive data in phase 3 cholesterol trial

On average, evinacumab reduced patients' LDL cholesterol in half and was generally well-tolerated in the trial," said George Yancopoulos, president and chief scientific officer of Regeneron. ... These results raise the potential that evinacumab may have

More from news
Approximately 45 fully matching, plus 654 partially matching documents found.

Latest Intelligence

The evolution of real-world studies

In the document, the EMA stated that it is fostering an ‘adaptive approach’ that uses real-world data to supplement clinical trial results. ... Ibrance gained a new approval based on data from EHRs and other real-world sources.
Streamlining clinical trials – why better data use is key

Blockchain is one possible trial data management solution. The technology creates a digital record of products or information as it is exchanged. ... Trial training. Patrick Pilch from BDO also sees collaboration and the establishment of common standards
#OrkambiNow?

Stressing that it is not possible to back up this ‘what if’ with hard data, he nevertheless he believes that access could have saved lives in that period. ... On the other hand, the trial data that Vertex submitted showed a relatively modest
Brain power: fresh approaches to Alzheimer’s drug discovery

competitive data, trial recruitment problems, and trial design that is ill-suited to making rapid progress against this elusive disease. ... The first proof-of-concept trial is expected to start in 2019 or 2020, and will include three interventions in
Why precision medicine demands precision engagement

This real-world information can help life sciences organisations understand the benefits and challenges of a treatment outside the controlled clinical trial environment and, together with scientific data, evolve treatments for ... Through this

More from intelligence
Approximately 0 fully matching, plus 46 partially matching documents found.

Latest appointments

Clinerion appoints new regional head

Bariş Erdoğan takes up new role at the clinical trial data firm. ... Swiss-based clinical trial data firm Clinerion has appointed Bariş Erdoğan as its new regional head in a role that focuses on the expansion of its activities in Eastern Europe, the
Sanofi CEO Viehbacher to head EFPIA

One of the most pressing matters for EFPIA is the seemingly inevitable trend towards transparency of trial data, and Viehbacher has already commented on the subject.
Eric Green named NIH's data science lead

Dr Eric Green, current director of the National Human Genome Research Institue (NHGRI), is to serve as the first associate director for data science at the US National Institutes for Health ... This project offers a data repository with demographics,
Almac appoints Charlie Morris as VP new products and services in clinical technologies division

According to the company, which provides services to the pharma industry, he will oversee the development of its IXRS technology to manage patients, supplies, and clinical trial data.

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

The relevance of patient perspectives to value: Patient Involvement in Health Technology Assessment

gains that are not captured in clinical trial data. ... Today, patient preference data from rigorously conducted studies are providing decision-makers with a wider pool of views on the outcomes that patients value.
Nucleus Global launches Nucleus POLAR™, a state-of-the-art expert search engine and engagement management tool

Nucleus POLAR is a fast, efficient and comprehensive way to identify and map external experts, providing expert profiles that combine publications, clinical trial and transfer of value data sets. ... We designed and built Nucleus POLAR ourselves using
Havas Lynx Group launches white paper on Clinical Trials Day to address $40bn clinical trials challenge

This approach puts the patient front and centre of the trial and seamlessly uses data technology and media to reduce the time and cost of finding and retaining patients. ... Patient Centricity on Trial’ reinforces this strategy and outlines six main
Three key development areas in the management of multiple sclerosis

Clinical trial and real-world data supporting the efficacy of disease-modifying therapies in newly diagnosed and early MS were presented at the ECTRIMS congress. ... The data showed that the majority of patients remained free from confirmed disability
More tell, less sell: HCP-centric comms

Content requested by HCPs[8]:. Journal reprints. Diagnostic instruments. Clinical trial data. ... clinical trial data, disease information, and journal reprints.[8].